anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Preventing positive margins is essential for ensuring favorable patient outcomes following breast-conserving surgery (BCS). Deep learning has the potential to enable this by automatically contouring the tumor and guiding resection in real time. However, evaluation of such models with respect to pathology outcomes is necessary for their successful translation into clinical practice.
METHODS: Sixteen deep learning models based on established architectures in the literature are trained on 7318 ultrasound images from 33 patients. Models are ranked by an expert based on their contours generated from images in our test set. Generated contours from each model are also analyzed using recorded cautery trajectories of five navigated BCS cases to predict margin status. Predicted margins are compared with pathology reports.
RESULTS: The best-performing model using both quantitative evaluation and our visual ranking framework achieved a mean Dice score of 0.959. Quantitative metrics are positively associated with expert visual rankings. However, the predictive value of generated contours was limited with a sensitivity of 0.750 and a specificity of 0.433 when tested against pathology reports.
CONCLUSION: We present a clinical evaluation of deep learning models trained for intraoperative tumor segmentation in breast-conserving surgery. We demonstrate that automatic contouring is limited in predicting pathology margins despite achieving high performance on quantitative metrics.
The tooth mould unit has a recess (5), which corresponds to a negative pattern of an artificial tooth to be moulded. The mould unit hardens a chemically-hardenable material e.g. silicone, in the recess to mold the tooth. The material corresponds to the color, opalescence of the artificial tooth. A base unit (12) made of metal mechanically supports the tooth mould unit and includes a light source and an optical fiber coupling. An independent claim is also included for a method for manufacturing an artificial tooth.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. If left untreated, MASLD can progress from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis, which is characterized by inflammation and fibrosis. Current treatment options for MASLD remain limited, leaving substantial unmet medical needs for innovative therapeutic approaches. Here, we show that PLIN2, a lipid droplet protein inhibiting hepatic lipolysis, serves as a promising therapeutic target for MASLD. Hepatic PLIN2 levels were markedly elevated in multiple MASLD mouse models induced by diverse nutritional and genetic factors. The liver-specific deletion of Plin2 exhibited significant anti-MASLD effects in these models. To translate this discovery into a therapeutic application, we developed a GalNAc-siRNA conjugate with enhanced stabilization chemistry and validated its potent and sustained efficacy in suppressing Plin2 expression in mouse livers. This siRNA therapeutic, named GalNAc-siPlin2, was shown to be biosafe in mice. Treatment with GalNAc-siPlin2 for 6-8 weeks led to a decrease in hepatic triglyceride levels by approximately 60% in high-fat diet- and obesity-induced MASLD mouse models, accompanied with increased hepatic secretion of VLDL-triglyceride and enhanced thermogenesis in brown adipose tissues. Eight-week treatment with GalNAc-siPlin2 significantly improved hepatic steatosis, inflammation, and fibrosis in high-fat/high fructose-induced metabolic dysfunction-associated steatohepatitis models compared to control group. As a proof of concept, we developed a GalNAc-siRNA therapeutic targeting human PLIN2, which effectively suppressed hepatic PLIN2 expression and ameliorated MASLD in humanized PLIN2 knockin mice. Together, our results highlight the potential of GalNAc-siPLIN2 as a candidate MASLD therapeutic for clinical trials.
Yoga practice has shown benefits in treating multiple physical or mental disorders (Barnes, Bloom, \& Nahin, 2008; Khalsa, 2004; Ross, Friedmann, Bevans, \& Thomas, 2013) and has recently been evaluated for PTSD. We identified six randomized controlled studies measuring the effect of yoga in women (mostly) who experienced childhood violence (see table). With the exception of one pilot study (Dick, Niles, Street, Dimartino, \& Mitchell, 2014; Mitchell et al., 2014), all studies show a significant reduction in PTSD symptoms compared to the pre-treatment period and compared to the control group (waiting list group). In particular, it was shown that this reduction in symptomatology was comparable to that of other commonly practiced psychotherapies, such as the exposure techniques of Behavioural and Cognitive Therapies or EMDR, and comparable to pharmacological treatments (Van Der Kolk et al., 2014). Prolonged yoga therapy would also significantly improve dissociative symptoms (Price et al., 2017). However, all these studies tested the effect of yoga therapy in isolation, without associating it with conventional and recommended treatments for trauma. However, given the fields of action of the yoga listed above, we think that it could be the ideal tool to prepare (in the pre-treatment phase) the work on traumatic memory. We believe that the combination of yoga therapy and EMDR would work in synergy to reduce complex PTSD and achieve a higher success rate than these individual approaches. In this work, we will use a yoga technique adapted to the treatment of psycho-trauma called "trauma sensitive yoga" (Emerson, 2015).
PURPOSE: To provide a potency improving process comprising the administration of an indirect sympathetic agent capable of improving a certain kind of potency in combination with tyrosine or a tyrosine precursor and provide a composition therefor. £ Synergistic effect, additive effect, agility. CONSTITUTION: This composition is effective for improving a potency, e.g. increasing self-conscious activity, relieving fatigue, decreasing confusion and suppressing tension and anxiety. The composition is composed of an indirect sympathetic agent and tyrosine or a tyrosine precursor. The indirect sympathetic agent is phenylpropanolamine, amphetamine or ephedrine. Tyrosine increases the potency increasing activity of known indirect sympathetic agent.
The invention discloses a sunscreen agent of composite silicon dioxide, which comprises the following components, by weight, 5-95 parts of silicon dioxide and 5-95 parts of sunscreen agent. The silicon dioxide is porous silicon dioxide microspheres, and the particle size of the porous silicon dioxide microspheres is 10 nanometers to 100 micrometers. The sunscreen agent is one or more of physical sunscreen agent, chemical sunscreen agent, and natural plant sunscreen agent. The sunscreen agent of the composite silicon dioxide has the advantages of broad-spectrum sunscreen, wide applicability, safety, no stimulation and strong stability in a formula, and can be directly dispersed in a water phase, so that the sunscreen index of a product can be greatly improved, and the sunscreen agent can be completely used without worry because the components are natural and do not generate harm to the ecological environment. Can be applied to water phase in oil-in-water system, oil phase in water-in-oil system, and powder cosmetic. The application range is very wide.
PROBLEM TO BE SOLVED: To obtain a cosmetic which has low irritation to skins, solubilizes transparently and shows improved penetration to skins and stability by including a salt which is composed of a sphingosine (derivative) and an inorganic acid or the like and has a lower melting point than that of the sphingosine (derivative). SOLUTION: This cosmetic is obtained by including a salt which is composed of (A) a sphingosine (derivative), e.g. dehydrosphingosine or the like and (B) an inorganic acid, e.g. hydrofluoric acid or the like, or a 1-17C organic acid, e.g. lactic acid or the like, and has a lower melting point than that of the sphingosine (derivative). Further, the components A and B are preferably formulated in the range of the components A/B=1/0.3-1/5 in the molar ratio. Furthermore, it is favorable that the melting point of the sphingosine (derivative) is more than 40 deg.C and the components A and B are blended in proportions of 0.01-3 wt.% and 0.001-3 wt.%, respectively, based on the whole weight of the composition.
The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (\<33%) patients of a 6 patient cohort.
THE APPLICATION OF PHOSPHORYLATION OF C200RF112 PROTEIN AT SER295 IN DETECTING CANCER CELL PROLIFERATION 5 The present invention discloses a use of phosphorylation of a C200rfl 12 protein at Ser295 in regulation of cancer cell proliferation. By in vitro experiments, the present invention has found that the high expression of C200rfl 12 can promote proliferation of colorectal cancer cell and formation of colorectal cancer tumor sphere, and phosphorylation of C200rf1 12 at Ser295 10 can inhibit proliferation and growth of colorectal cancer cell. In addition, by in vivo experiments, the present invention has further found that a nude mouse subcutaneous tumor is regulated by phosphorylation of C200rf 112 at Ser295, that is, phosphorylation of C200rf1 12 at Ser295 can inhibit growth of bowel cancer tumor. The molecular mechanism of C200rf1 12 phosphorylated at Ser295 in tumorigenesis of colorectal cancer that is provided in the present invention lays a 15 theoretical foundation for the research on tumorigenesis and precise treatment for colorectal cancer. Fig. 6
Participants received desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection began on day 6.
PURPOSE:The titled emulsion for remedying skin diseases, having improved thermal stability, and long-term storage with scarcely found reduction in content due to decomposition of main drug, containing polyoxyethylene polyoxypropylenecetyl ether as an emulsifying agent. CONSTITUTION:A water-in-oil type emulsion of steroid-based drug (preferably corticosteroid such as budesonide, betamethasone valerate, etc.) containing polyoxyethylene polyoxypropylenecetyl ether as an emulsifying agent. The emulsion can stand long-term storage at high temperature. White vaseline, liquid paraffin, olive oil, stearic acid, stearyl alcohol, etc. is used as an oily phase component for the emulsion, and a common additive such as an antiseptic, stabilizer, solubilizer, humectant, pH adjustor, etc. may be added to the emulsion.
A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 or Day 2 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m\^2 + gemcitabine 1000 mg/m\^2 + oxaliplatin 100 mg/m\^2 every 2 weeks (Q2W) for up to 8 cycles.
BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) represents a hyperinflammatory state that can result in multi-organ dysfunction and death. Myeloid-derived suppressor cells (MDSC) are an immunosuppressive cell population that expands under inflammatory conditions and suppresses T cell function. We hypothesized that MDSC would be increased in children with MIS-C and that MDSC expansion would be associated with T cell lymphopenia.
METHODS: We conducted a prospective, observational study. Initial blood samples were collected within 48 h of admission. Age-matched healthy controls underwent sampling once. MDSC and T cell populations were identified by flow cytometric methods.
RESULTS: We enrolled 22 children with MIS-C (12 ICU, 10 ward) and 21 healthy controls (HC). Children with MIS-C demonstrated significantly higher MDSC compared to HC, and MDSC expansion persisted for >3 weeks in the ICU group. Children with MIS-C admitted to the ICU demonstrated significantly lower absolute numbers of T cells and natural killer cells. There were no significant associations between MDSC and cardiac dysfunction, duration of hospitalization, or vasoactive inotrope score.
CONCLUSIONS: Our study suggests that children critically ill with MIS-C have expansion of MDSC and associated decreased T cell and NK cell populations. Our results did not demonstrate associations between MDSC and clinical outcomes.
IMPACT: Multisystem inflammatory syndrome in children (MIS-C) is a dysregulated immune response occurring several weeks after SARS-CoV-2 infection that can result in multi-organ dysfunction and death. Children severely ill with MIS-C demonstrated increased myeloid-derived suppressor cells and decreased absolute numbers of CD4+ and CD8 + T cells and NK cells compared to healthy controls. There was no significant association between MDSC numbers and clinical outcomes; including cardiac dysfunction, length of stay, or requirement of vasoactive support, in children with MIS-C.
FIELD: treatment of chronic diseases of respiratory tracts. SUBSTANCE: the cassette has a built-in dosing apparatus with a dosing cavity for placement of the preset quantity of powder pharmaceutic preparation, means for feeding of cleaning air and provision of complete emptying of the dosing apparatus dosing cavity in the emptying position. The built-in dosing apparatus comprises a dosing slider located below the reservoir for keeping of powder pharmaceutic preparation and installed for movement from the filling position to the emptying position in lateral direction relative to the direction of flow of powder pharmaceutic preparation to the dosing cavity. The dosing slider is installed for directing the flow of powder of the pharmaceutic preparation from the above reservoir to the dosing cavity of the dosing slider by gravity. The inhaler has a vessel for the cassette and a drive of the slider of the built-in dosing apparatus. EFFECT: enhanced safety of treatment and convenience of use. 45 cl, 16 dwg
In period 1, patients will receive a single 100 mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1 then daily 100-mg doses on days 2 through 42.
Corticosteroid combined with cytotoxic drugs has been regarded as the conventional therapy for Class IV Lupus Nephritis (LN), because of its efficacy in improving patients' long term survival. However, this treatment fails in some patients, especially those who present with significant vascular lesion. In addition, cyclophosphamide (CTX) has severe side effects with a high incidence of marrow inhibition and infection.FK506 (Tacrolimus) is a new calcineurin inhibitor. Similar to Cyclosporine (CsA), it inhibits the production of IL-2 and activation of T cells. Furthermore, it has an added value of inhibiting the production of IL-10 from Th2 cells, thus reducing the production of auto antibodies from B cells.It also exerts its specific immunosuppressive effects through CsA-insensitive pathway. FK506 could inhibit not only the activation of naive T cells but also the activation and proliferation of primed T cells.FK506 is 10 -100 times more powerful than CsA in inhibiting the activation of T cells.Animal studies on MRL/lpr mice LN model demonstrated that FK506 could significantly depress the excretion of urine protein and the level of serum anti-dsDNA, inhibit glomerular cellular proliferation and formation of crescents, and reduce the deposits of immune complex.

A preliminary study showed that FK506 was significantly effective on patients with IV LN,as indicated by rapid reduction of urine protein, increase in serum albumin, decrease in auto antibodies together with remission of lesion activity of the renal tissue. However, the drawbacks of this study were the small sample size and the lack of a controlled group. Hence, a multi-center controlled study comparing FK506 with cytotoxic agents to evaluate the efficacy and safety of FK506 on patients with III or IV LN, and explore the effective range of FK506 blood concentration and the appropriate target patient population would be needed.
For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 20cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
BACKGROUND: Although previous observational studies have shown an association between venous thromboembolism (VTE) and atrial fibrillation (AF), the underlying causal relationship between them remains uncertain.
METHODS AND RESULTS: This two-sample bidirectional Mendelian randomization (MR) analysis was performed to investigate the causal relationship between VTE and AF. The VTE dataset were obtained from FinnGen, including 9,176 cases and 209,616 controls. Meanwhile a genome-wide association study (GWAS) of 60,620 individuals with AF and 970,216 control subjects identified genetic variations associated with AF. The principal MR analytic approach used in this study is the inverse-variance weighting (IVW) method. Furthermore, we performed complementary MR analyses, including the MR-Egger, Weighted median (WM), and Weighted Mode. MR pleiotropy residual sum was applied to identify pleiotropy. The MR analysis showed suggestive causal associations between VTE and the risk of AF (p = 0.0245, OR [95%CI]: 1.027 [1.003, 1.051]). The reverse MR analysis found that genetic susceptibility to AF was not significantly associated with VTE, as determined by the IVW method (p = 0.7773). The robustness of these findings was corroborated through MR sensitivity analyses.
CONCLUSIONS: There is a unidirectional causal relationship between VTE and AF, meaning that VTE is a causal risk factor for AF, whereas no effect of AF on VTE was identified.
The invention relates to a Chinese medical patch for preventing carsickness. The invention effectively solves the carsickness problem for mass by bus, plane and ship. The technical proposal of the invention is that the patch is made of Chinese medicines such as dried ginger, falangal, fennel fruit, angelica dahurica, tsaoko amomum fruit, tangerine peel and malt, and gauzes or other replacing objects; wherein, the medical materials are soaked in water and then are boiled into Chinese medical liquid; the gauzes or other replacing objects are dipped into the Chinese medical liquid for soaking; the gauzes or other replacing objects are dried or dried naturally at low temperature after being fully soaked, and then are cut into blocks which are arranged on adhesive fabrics; and finally the blocks are packaged with the plastic membranes which are used as protective layers. When in use, the protective layer is torn off; and the medical patch is stuck on the navel 30 to 60 minutes before going on a bus. The invention has the advantages of easy use, good effect, easy production, and satisfying the demands of the mass. The invention is a great breakthrough in the field of carsickness prevention, thereby being beneficial for human being.
Mastitis is a significant factor that decreases milk production in cows of different breeds in Kazakhstan. The objective of this study was to determine the genetic makeup of Holstein cows by analysing specific gene loci (SELL, MX1, CXCR1+291C>T and CXCR1+1093C>T) that are linked to resistance against mastitis. The goal was to identify cows with favourable genotypes that are less prone to udder diseases. At the SELL gene locus c.567T>C, all three genetic variants were identified in the control population with the respective frequencies: TT (0.20), CT (0.44), and CC (0.36). Genetic variation was also detected at the MX1 gene c.567T>C, CXCR1 c.+291C>T and CXCR1+1093C>T loci. Deviation from the expected Hardy-Weinberg equilibrium was observed for two gene loci, MX1 g.143182088 and CXCR1+1093C>T, with increased chi-square values of 10.6261 and 9.7137, respectively. The analysis of subclinical mastitis incidence indicates that cows carrying the heterozygous CT genotype at the L-selectin gene locus exhibit greater resistance to the disease. Animals carrying the CCCCCT genotype at the MX1 c.567T>C, CXCR1 c.+291C>T and CXCR1+1093C>T gene loci were discovered to have a significant likelihood of developing subclinical mastitis. This suggests that these genes could serve as potential indicators of susceptibility to the condition. The practical significance of this study lies in determining the frequency of genotypes linked to mammary gland morbidity in Holstein breeding farms in Kazakhstan.
Hypertensive individuals who meet the inclusion and exclusion criteria will note their blood pressure values 2 days a week for 8 weeks and share them with the physiotherapist. Patients in this group will be instructed to continue their normal lives.
We previously reported that enhanced corticotropin-releasing factor (CRF) signaling in the bed nucleus of the stria terminalis (BNST) caused the aversive responses during acute pain and suppressed the brain reward system during chronic pain. However, it remains to be examined whether chronic pain alters the excitability of CRF neurons in the BNST. In this study we investigated the chronic pain-induced changes in excitability of CRF-expressing neurons in the oval part of the BNST (ovBNSTCRF neurons) by whole-cell patch-clamp electrophysiology. CRF-Cre; Ai14 mice were used to visualize CRF neurons by tdTomato. Electrophysiological recordings from brain slices prepared from a mouse model of neuropathic pain revealed that rheobase and firing threshold were significantly decreased in the chronic pain group compared with the sham-operated control group. Firing rate of the chronic pain group was higher than that of the control group. These data indicate that chronic pain elevated neuronal excitability of ovBNSTCRF neurons.